Details for New Drug Application (NDA): 206974
✉ Email this page to a colleague
The generic ingredient in LAMIVUDINE is lamivudine; nevirapine; zidovudine. There are twenty-nine drug master file entries for this compound. Additional details are available on the lamivudine; nevirapine; zidovudine profile page.
Summary for 206974
Tradename: | LAMIVUDINE |
Applicant: | Upsher Smith Labs |
Ingredient: | lamivudine |
Patents: | 0 |
Pharmacology for NDA: 206974
Mechanism of Action | Nucleoside Reverse Transcriptase Inhibitors |
Medical Subject Heading (MeSH) Categories for 206974
Suppliers and Packaging for NDA: 206974
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
LAMIVUDINE | lamivudine | TABLET;ORAL | 206974 | ANDA | Ingenus Pharmaceuticals, LLC | 50742-623 | 50742-623-60 | 60 TABLET in 1 BOTTLE, PLASTIC (50742-623-60) |
LAMIVUDINE | lamivudine | TABLET;ORAL | 206974 | ANDA | Ingenus Pharmaceuticals, LLC | 50742-624 | 50742-624-60 | 30 TABLET in 1 BOTTLE, PLASTIC (50742-624-60) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 150MG | ||||
Approval Date: | Nov 21, 2016 | TE: | AB | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 300MG | ||||
Approval Date: | Nov 21, 2016 | TE: | AB | RLD: | No |
Complete Access Available with Subscription